Exact Sciences (EXAS) Stock Forecast, Price & News

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EXAS shares.
View EXAS analyst ratings or view top-rated stocks.

14 Wall Street analysts have issued 12 month price objectives for Exact Sciences' shares. Their EXAS share price forecasts range from $60.00 to $130.00. On average, they predict the company's stock price to reach $97.00 in the next twelve months. This suggests a possible upside of 45.1% from the stock's current price.
View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts.

Exact Sciences' stock was trading at $49.51 at the beginning of the year. Since then, EXAS shares have increased by 35.0% and is now trading at $66.85.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our EXAS earnings forecast.

Exact Sciences Co. (NASDAQ:EXAS) released its quarterly earnings results on Tuesday, August, 1st. The medical research company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.05. The medical research company had revenue of $622.10 million for the quarter, compared to analysts' expectations of $601.14 million. Exact Sciences had a negative net margin of 18.76% and a negative trailing twelve-month return on equity of 14.08%. The company's revenue was up 19.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.94) EPS.

ETFs with the largest weight of Exact Sciences (NASDAQ:EXAS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ARK Innovation ETF (ARKK), Principal Healthcare Innovators ETF (BTEC), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Simplify Health Care ETF (PINK), First Trust NYSE Arca Biotechnology Index Fund (FBT) and VanEck Biotech ETF (BBH).

Exact Sciences updated its FY 2023 earnings guidance on Wednesday, June, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.40 billion-$2.40 billion, compared to the consensus revenue estimate of $2.42 billion.

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Exact Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (3.96%), Capital World Investors (3.76%), Baillie Gifford & Co. (2.53%), Artisan Partners Limited Partnership (1.96%), Geode Capital Management LLC (1.49%) and Sumitomo Mitsui Trust Holdings Inc. (1.47%). Insiders that own company stock include Brian Baranick, Canada Pension Plan Investment, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy, Sarah Condella and Torsten Hoof.
View institutional ownership trends.

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EXAS stock can currently be purchased for approximately $66.85.

Exact Sciences (NASDAQ:EXAS) has a market capitalization of $12.08 billion and generates $2.08 billion in revenue each year. The medical research company earns $-623,510,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis.

The company employs 6,400 workers across the globe.

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701.